Prestige Consumer Q3 revenue slightly beats expectations

Overview

• Consumer healthcare firm's Q3 revenue slightly beat analyst expectations

• Adjusted EPS for Q3 met analyst expectations

• Company closed acquisition of Pillar5 Pharma and repurchased 0.8 mln shares

Outlook

• Prestige narrows fiscal 2026 revenue outlook to approximately $1.1 bln

• Company maintains fiscal 2026 free cash flow forecast of $245 mln or more

• Prestige expects supply improvements for Clear Eyes to support long-term demand

Result Drivers

• CLEAR EYES® SUPPLY ISSUES - Revenue decline driven by limited ability to supply demand for Clear Eyes®, impacting Ear & Eye Care sales

• PILLAR5 ACQUISITION - Completed acquisition of Pillar5 Pharma, expected to improve eye care supply chain

• SHARE REPURCHASE - Repurchased 0.8 mln shares in Q3, leveraging strong free cash flow and low leverage

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc is $76.00, about 13.4% above its February 4 closing price of $67.03

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nGNXbvCCgL

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.